Page 14 - Pharma Companies

Contract drug maker V-Ensure gets Rs 130 cr from Investcorp, Tanas Capital

Founded in 2010, V-Ensure is into specialty pharmaceutical formulations focused on complex generics for regulated markets

Purdue's Sacklers boost opioid settlement offer up to $6 billion

As part of the deal, Purdue will hand over nearly all of its assets to the states, cities and counties that are suing the drugmaker over its handling of the pain killer OxyContin

Mankind Pharma acquires two derma and respiratory brands from Dr Reddy's

Mankind Pharma to take over manufacturing, marketing and distribution of both products in India; entire integration and transition of the brands likely to be completed by March

Macleods Pharma files DRHP for second largest IPO by drug co at Rs 5,000 cr

It is entirely an offer for sale or OFS, company won't receive any of the proceeds

Strides Pharma records net loss of Rs 122 cr in Q3, revenue drops 5%

Company expects growth momentum in the US to pick up in coming quarters driven by new product launches

Pricing trend, launches, stability of growth boosters for Dr Reddy's

Near-term outlook and valuation are expected to support the stock price

Cipla Q3 PAT dips 2.6% at Rs 729 crore

Drug major Cipla on Tuesday reported a 2.6 per cent decline in its consolidated profit after tax to Rs 729 crore for the third quarter ended on December 31, 2021. The Mumbai-based company had posted a consolidated profit after tax (PAT) of Rs 748 crore in the October-December quarter of 2020-21 fiscal. Total revenue from operations, however, rose by 6 per cent to Rs 5,479 crore in the third quarter as compared with Rs 5,169 crore in the same period of last fiscal, Cipla said in a regulatory filing. "I am pleased to see the strong launch and commercial momentum across our core markets during the quarter. Our portfolio execution in branded markets of India and South Africa and strong respiratory traction driving our US generic franchise to a multi-quarter high quarter were key drivers," Cipla MD and Global CEO Umang Vohra noted. The unlocking of the company's first peptide asset, lanreotide injection is an important step in strengthening complex generics engine, inching up the drug .

Omicron spread: Pfizer seeks conditional EU authorisation for Covid-19 pill

The announcement comes as countries in much of the 27-nation bloc are reporting soaring numbers of infections

Brinton Pharma to launch generic version of anti-Covid pill Molnupiravir

The company will introduce it in the domestic market under the brand 'Molviton'

Pharma firm Venus Remedies makes the cut for PLI Scheme

Under this scheme, Venus Remedies will make a committed investment in plant and machinery, get incentives on incremental sales of pharmaceutical products

Pharma major Lupin announces launch of its diagnostics business

Homegrown pharma major Lupin Ltd on Friday announced the launch of its diagnostics arm as part of its strategy to provide integrated healthcare in India.

Drug maker Lupin inks pact to distribute, market Pegfilgrastim in Brazil

The company has entered into an exclusive distribution and marketing agreement with Biomm SA in Brazil

Australia's Woolworths makes $613 mln drugstore play, taking on Wesfarmers

The 11th-hour move from Woolworths sets the scene for a bid war between Australia's two largest retail companies

Multiple near-term concerns trigger Divi's Laboratories' headache

Pfizer's oral Covid drug, weak sales of generics, and valuations may cap upsides

Power crisis brewing in China likely to hit Indian pharma companies

Delays in consignments, rising prices of key ingredients worry industry

Germany's Boehringer, Indian pharma in legal battle over diabetes drug

The German drug maker has obtained interim injunctions against MSN Labs and Dr Reddy's Lab

M-cap of 2 demerged entities could exceed Piramal's by 10-15%: Analysts

Analysts say the demerger will make it easier for investors to value the two companies

Zydus Cadila gets USFDA nod to market depression treatment drug in US

Drug firm Zydus Cadila on Saturday said it has received approval from the US health regulator to market Vortioxetine Tablets, used to treat depression, in the American market.

Glenmark Pharma concludes study on Covid drug Favipiravir in India

Drug firm Glenmark Pharmaceuticals on Wednesday said it has successfully completed its post-marketing surveillance study on Favipiravir in India.

Work on non-Covid vaccines gives pharma firms an injection of hope

Approach drug regulator, seeking permission to conduct clinical trials